Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human interleukin-11 variant
- Development stage
- Unknown
- Lead developer
- Northland Biotech
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
NL-101 is a second-generation recombinant human interleukin-11 (rhIL-11) variant developed by Beijing Northland Biotech for the treatment of chemotherapy-induced thrombocytopenia (CIT). As a modified version of the native cytokine, NL-101 is engineered to maintain potent thrombopoietic activity while potentially improving the safety profile compared to first-generation rhIL-11 (oprelvekin), which is often limited by adverse effects such as fluid retention, edema, and cardiovascular complications. NL-101 acts as an agonist for the IL-11 receptor complex, which consists of the IL-11 receptor alpha (IL-11Rα) and the signal-transducing subunit gp130. Binding to this complex activates downstream signaling pathways, including the JAK/STAT cascade, which stimulates the proliferation of hematopoietic stem cells and the maturation of megakaryocytes into functional platelets. The drug is currently in Phase 3 clinical development in China.
- Other names
- rhIL-11 variantrhIL11 variantrhIL 11 variantrecombinant human interleukin-11 variant
02
Targets
IL11RA (Interleukin-11 receptor subunit alpha)IL6ST (Interleukin-6 receptor subunit beta)
Beyond the preview
Go deeper on recombinant human interleukin-11 variant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human interleukin-11 variant.